Skip to content

Trial Summary

The primary Phase 1 purpose of this study is to assess overall safety and tolerability and recommended Phase 2 dose (RP2D) of APL-101. The Phase 2 portion will assess efficacy of the dose determined in Phase 1 in individuals with Non-Small Cell Lung Cancer.

Acronym:

SPARTA

ACTRN/NCT /ethics:

NCT03175224

Scientific title:

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Sponsor / Cooperative group:

Apollomics Inc.

Trial & Patient Characteristics

Cancer TypeLung & mesothelioma; All cancers
Trial TypeTreatment
PhasePhase I; Phase II
Age Range18 years and older
SexBoth
Tumour Stream Non-Small Cell Lung Cancer
Cancer StageAll stages
Anticipated Start Date2017-09-27
Anticipated End Date2022-12-30

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlex Scott-Hoy
Emailalex.scott-hoy@sa.gov.au
Phone08 8204 4830
Principal InvestigatorDr Chris Karapetis
Recruitment StatusNot Yet Recruiting
HospitalCalvary Central Districts Hospital
Clinical Trial CoordinatorJulie Rowe
Emailjulie.rowe@calvarycare.org.au
Phone08 8239 9536
Principal InvestigatorDr Vineet Kwatra
Recruitment StatusRecruiting